Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482284 | 0.92 | NR1H4 (0.49) | NR1H4KCNH2PTGER1TBXA2RTHRA | |
| SCHEMBL1482104 | 0.92 | PTGER1 (0.45) | NR1H4KCNH2PTGER1 | |
| SCHEMBL1482644 | 0.91 | NR1H4 (0.43) | NR1H4KCNH2PTGER1TBXA2R | |
| SCHEMBL1482733 | 0.91 | NR1H4 (0.43) | NR1H4KCNH2PTGER1THRATHRB | |
| SCHEMBL1482610 | 0.89 | KMT2A (0.43) | NR1H4KCNH2PTGER1 | |
| SCHEMBL1482713 | 0.88 | NR1H4 (0.46) | NR1H4TBXA2R | |
| SCHEMBL1482376 | 0.88 | DRD2 (0.47) | NR1H4KCNH2PTGER1TBXA2R | |
| SCHEMBL1483039 | 0.88 | NR1H4 (0.49) | NR1H4PTGDR2KCNH2PTGER1 | |
| SCHEMBL1483174 | 0.87 | PTGER1 (0.50) | NR1H4KCNH2PTGER1 | |
| SCHEMBL1483423 | 0.86 | NR1H4 (0.42) | NR1H4KCNH2PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | claimed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | claimed |
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| WO-2011039130-A1 | NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-07 | — | — | WO | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | NR1H4 776/4885PTGDR2 1459/4885KCNH2 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.